Potential advantages of CD1-restricted T cell immunotherapy in cancer.
Mol Immunol. 2018 Nov;103:200-208. doi: 10.1016/j.molimm.2018.09.025. Epub 2018 Oct 8.
Mol Immunol. 2018.
PMID: 30308433
Review.